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The Gaedigk et al. article BA perspective by PharmVar: Are
the hundreds of CYP2D6 haplotypes predicted by Wendt and
colleagues real?^ describes shortcomings of the 2017 Wendt
et al. article BFull-gene haplotypes refine CYP2D6
metabolizer phenotype inferences^ [1]. To summarize, they
discuss (1) the lack of submission of novel variants to www.
PharmVar.org; (2) inaccurate activity score reporting, namely
for those haplotypes containing the 843T>G SNP; (3) use of
1000 Genomes Project (1kGP) data from the inaccessible re-
gions of the database; and (4) lack of sequence and structural
validation for any of the described haplotypes.
We thank Gaedigk and colleagues for their review of the
Wendt et al. 2017 findings and in many ways share their con-
cerns. In general, the authors’ letter raises valid concerns for
the data presented in the original Wendt et al. study and many
pharmacogenomics studies utilizing publically available data.
However, the authors’ appear to overstate our reported find-
ings and seem to ignore where we already transparently dis-
cuss the major limitations of using such a database for this
type of data exploration.
We summarize our responses to their concerns below. In gen-
eral, we urge PharmVar to actively update its nomenclature table
as to reflect most recent submitted findings. Additionally, we
encourage PharmVar, its affiliates, and other pharmacogenomics
researchers to release full-gene information as it becomes avail-
able, rather than only those sites relevant to the PharmVar no-
menclature table(s) or the repository of knowledge for their re-
spective gene(s) of interest. In doing so, the initiative described
by Gaedigk and colleagues will continue to thrive.
The Wendt et al. paper was intended to explore the use of
full-gene CYP2D6 haplotype diversity in publically available
data. A number of single-nucleotide polymorphisms from the
1kGP and the Wendt et al. study are not found on www.
PharmVar.com. Gaedigk and colleagues note that PharmVar
accepts submission of high-quality haplotype data. The Pilot
Criteria of the 1kGP Phase3 Paired-end Accessible Regions
are quite stringent, requiring Ba depth of coverage between
8,960 and 35,840 inclusive (between one-half and twice the
average depth) and that no more than 20% of covering reads
have mapping quality zero^ [2]. Indeed, read depth is a limit-
ing factor for using data such as those of the 1kGP; however,
Wendt et al. never recommended or even suggested that the
data were high quality and be considered for submission to
PharmVar. Such a recommendation would have been inappro-
priate and misleading to the community. Indeed, we stress in
our paper that Bempirical data are required to confirm their
enzyme activity [of the resulting haplotypes]^ and thus share
similar concerns. Wendt et al. indicated that the relatively low
sequencing read depth of the 1kGP is a major limitation of
their findings. However, low read depth of pharmaco- and
immunogenes does not warrant ignoring the public availabil-
ity of 1kGP short-read data for exploratory purposes. It is a
great resource used by many scientists for developing hypoth-
eses and addressing probing questions.
There appears to be some confusion by Gaedigk et al. re-
garding the methods ofWendt et al. in which 1kGP haplotypes
were characterized first using only those sites recognized and
published on the PharmVar website (Human Cytochrome
p450 Allele Nomenclature Database at the time of Wendt et
al. analyses). Here, the consortium defines CYP2D6
* Frank R. Wendt
frw5010@gmail.com
1 Center for Human Identification, University of North Texas Health
Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107,
USA
2 Graduate School of Biomedical Sciences, University of North Texas
Health Science Center, 3500 Camp Bowie Blvd., Fort
Worth, TX 76107, USA
3 Laboratory of Forensic Biology, Department of Forensic Medicine,
University of Helsinki, P.O Box 40, 00014 Helsinki, Finland
4 Instituto de Biologia, Universidade Federal do Rio de Janeiro, Rio de
Janeiro 21941, Brazil
International Journal of Legal Medicine (2019) 133:807–810
https://doi.org/10.1007/s00414-018-1874-9
haplotypes and the functional consequences of each. These
data were used to assign an activity score to each 1kGP sam-
ple. Second, Wendt et al. used multiple variant effect predic-
tion algorithms to predict the function of all single-nucleotide
variants including those recognized and empirically evaluated
by PharmVar [3]. We used the activity score assigned to each
participant, consistent with PharmVar, and evaluated the in-
clusion of additional variants in the haplotype, producing best-
and worst-case predictions of functional impact on the
enzyme.
The haplotypes containing the 843T>G SNP certainly con-
found the data presented in Wendt et al. and contradict
existing literature. It should be noted that pathogenicity is
quite difficult to predict and variant effect prediction algo-
rithms have demonstrable error rates [4]. In fact, we urged
caution of those haplotypes containing 843T>G as Bthe
843G SNP was incorrectly identified as damaging [by the
variant effect predictors], emphasizing the importance of
using [multiple] variant effect predictors with caution.^
Thus, Wendt et al. do not mislead the community regarding
the functional consequence of 843T>G and emphasized cau-
tion in their discussion to infer functional consequences based
on variant effect predictions. Indeed,Wang et al. [5] were cited
who suggested revisiting definitions of certain CYP2D6* al-
leles following interrogation of new haplotypes. As high-
quality full-gene haplotype data are generated beyond the
Wang et al. pediatric cohort, some previous definitions will
likely evolve [5, 6].
The 3384A>C polymorphism was not detected in any of
our haplotypes due to lack of reporting this locus by the 1kGP
(Fig. 1). The 1kGP states that lack of genotype data for a locus
indicates lack of detectable variation at the locus considering
application of the strict-level stringency criteria. Personal
communication with the HelpDesk suggests that there is no
way to extract variant calling information for these sites.
Gaedigk and colleagues raise an important concern that the
alternate allele was not reported. This observation is also true
for the genotype data at many other PharmVar loci, including
− 1109C>T, − 960G>C, − 629A>G, − 98C>T, and 14C>T
[3]. As described above and by Gaedigk and colleagues, the
lack of variation at these loci also may be a result of low read
depth at many sites in the genome. However, Gaedigk and
colleagues allow us herein again to caution that the data are
exploratory, and such databases do have limitations of which
we were fully aware.
The SNP rs267608275 C-deletion is not indicated as a
defining SNP in the PharmVar CYP2D6 webpage [3] and
therefore was not considered in the analysis using PharmVar
recognized loci even though Gaedigk and colleagues indicate
in vivo data for enzyme functionality forCYP2D6*29.We use
*29 as an example in our study but likely rs267608275delC
may be observed in non-*29 haplotype conditions that have
not been observed to date. Based on variant effect prediction
for the locus, it is indicated as a damaging polymorphism.
While in vivo data may contradict this finding, Wendt et al.
reported best and worst-case enzyme function predictions. In
doing so, the best-case scenario treats rs267608275 as lacking
any functional consequence (as Gaedigk and colleagues dis-
cuss and the literature currently support). In contrast, it may be
possible that in certain populations, currently unobserved or
non-*29 haplotypes, or following exposure to emerging
drug(s) that this locus may result in decreased activity of the
enzyme [6], warranting a worst-case activity score of 0.Wendt
et al. had no intention of mitigating the work that has gone into
functional studies ofCYP2D6*29 or rs267608275 C-deletion,
but instead incorporated additional functional possibilities,
that may not have been observed yet by PharmVar, by using
models generated from well-established, but certainly limited,
variant effect predictors.
The M33388 reference sequence may not truly exist due to
sequencing errors; however, this also may be due to lack of
sampling enough individuals or enough individuals of the
appropriate population(s) to observe the M33388 haplotype.
Additionally, the CYP2D6 community utilizes positional in-
formation from this reference to align variants [3, 7]. As such,
it seems appropriate to report similarities to this reference
sequence. It also should be noted that Wendt et al. aligned
haplotypes to the M33388 and AY545216 reference se-
quences and the GRCh37 and GRCh38 reference genomes
(Wendt et al. [1] Supplemental Table 2) to minimize
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Fig. 1 University of California Santa Cruz (UCSC) Table Browser
screenshot showing the two single-nucleotide variants rs57175590 and
rs28578778 (M33388:3408A>G and M33388:3393A>G, respectively)
but not rs1985842 (M33388:3384T>G). The vertical red box indicates
the position where one would expect to observe the rs1985842 locus
community confusion and maximize comparisons of 1kGP
data with other reference sequences.
Gaedigk and colleagues are correct that the inaccessible
regions of the genome are problematic. However, we disagree
that they should be ignored or wholesale rejected. Ideally, the
1kGP should contain continuous reads and/or high read depth
to provide substantially greater confidence in haplotype calls
for pharmaco- and immunogenomic targets (e.g., CYP family
enzymes, human leukocyte antigen, toll-like receptors, estro-
gen receptors, etc.). However, again from an exploratory per-
spective, there is no justification for rejecting the 1kGP
Binaccessible regions^ on the basis of low genotyping confi-
dence. As described above, relatively stringent quality thresh-
olds have been applied to the data, and certainly all of
CYP2D6 does not meet them. In fact, only 38/417 loci used
to define our haplotypes fall below the pilot-level stringency
application. In the discussion, Wendt et al. note that their find-
ings should be used with caution, while emphasizing that poor
genotyping and computational phase confidence of the 1kGP
are issues. Our initial study does not ignore these limitations
but instead is quite transparent about them.
Lastly, Wendt et al. state that BAlthough empirical data are
required to confirm their enzyme activity, approximately 11%
of healthy individuals may be wrongly identified as NMs ac-
cording to traditional CYP2D6 genotyping and activity score
predictions.^ We stressed that empirical studies on full-gene
haplotype interrogation are needed as opposed to
recommending the findings be applied to immediate clinical
and case-work applications. We agree that validating haplo-
type observations is essential to making strong claims about
their clinical influence, and indeed the community is working
towards such endeavors (which is indicated by Gaedigk and
colleagues). Gaedigk et al.’s recommendation for validation
by Sanger sequencing to verify the 1kGP haplotypes is be-
yond the scope of our 1kGP data exploration and does not
overcome many of the issues presented by Gaedigk and col-
leagues related to CYP2D6 structural variants or appropriate
phase estimates. While Sanger sequencing certainly may be
one avenue, there are a number of next generation sequencing
technologies that can provide phasing and high read depth
with much higher throughput. Moving forward, gene se-
quencing with massively parallel sequencing will more likely
become the standard.
Gaedigk and colleagues highlight that copy number varia-
tion and adjacent gene rearrangements must be taken into
consideration for the locus, and we agree with and did address
this limitation of the 1kGP in stating that BCopy number var-
iations (CNV) of some CYP2D6* alleles and CYP2D7
pseudogene conversion do occur in some individuals, namely
UMs, and may influence the HWE and LD results [of this
study]. It is likely that some 1000 Genomes Project individ-
uals from the AFR super-population carry CNVs based on
deviations from HWE expectations, but the project does not
explore CNV in detail due to limitations of short-read se-
quencing. The data presented have been analyzed as though
only two copies of CYP2D6 are present in each individual…^
we continued by stating that BA number of unique haplotypes
have been identified that may be true haplotype observations
but may also be attributed to duplication of two common
haplotypes and/or CYP2D7 pseudogene conversion. This is
particularly true for the African populations which exhibit
relatively frequent gene duplications.^ To indicate that Bnone
of the latter were taken into account byWendt and colleagues^
is a gross misrepresentation of the discussions provided by
Wendt et al.
Gaedigk and colleagues, on behalf of PharmVar, raised a
number of concerns in which we are in full agreement and
discussed in our paper. Their position about recommendations
and use byWendt et al. are unfounded and are contraindicative
with the language and cautions raised within our study. It is
quite possible that many of the haplotypes reported are not real
due to limitations of the sequence data in the database, the
computational phase reportedly provided by the 1kGP, and
the variant effect prediction algorithms used by Wendt et al.
to make predictions. The field and capabilities are expanding
and we note that Shah and Gaedigk 2018 recently reinforced
the claim that Bpharmacogenetics was broadened by the ob-
servation that multifactorial genetic influences, in conjunction
with environmental factors, usually determine drug
responses,^ and that Bit is wise to expect that, even after we
have reached the goal to establish personalized medicine, we
will not have eliminated all uncertainties^ [8]. We presented
the findings of Wendt et al. as exploratory, and they should be
considered with the same caution and skepticism as any sci-
entist would use to evaluate the merit of other articles.
However, it is likely that substantially more CYP2D6 haplo-
types exist than are currently reported, especially considering
the incorporation of full-gene data currently not reported by
PharmVar. In fact, a recent report by Pratt et al. [6] discusses
this phenomenon in regard to the CYP2C19 locus. The com-
munity should continue to look at various avenues to expand
knowledge of the CYP2D6 pharmacogene.
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